Skip to content
Sign in

BBH · NASDAQ · ETF

VanEck Biotech ETF (BBH) Price, Holdings & Fees

$374.71−0.54%−$2.05End-of-day price as of Oct 9, 2026

VanEck Biotech ETF (BBH) closed at $374.71 on Oct 9, 2026, down 0.54% from the previous close of $376.76.

Share price, past year

1Y +15.51%

52-week range $317.31 – $378.50. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$374.71
Sep 30, 2026$366.48
Aug 31, 2026$356.50
Jul 31, 2026$356.96
Jun 30, 2026$365.73
May 29, 2026$350.77
Apr 30, 2026$348.08
Mar 31, 2026$352.52
Feb 27, 2026$359.34
Jan 30, 2026$350.15
Dec 31, 2025$343.26
Nov 28, 2025$319.73
Oct 31, 2025$335.00

Key statistics

Expense ratio
0.35%
as of Jan 31, 2026
Net assets
$395.6M
as of Jun 30, 2026
Holdings
25
as of Jun 30, 2026
52-week range
$317.31 – $378.50

VanEck Biotech ETF's expense ratio is 0.35%: $35.00 a year on $10,000 invested.

Holdings

VanEck Biotech ETF held 25 investments worth $395.55M as of Jun 30, 2026. Its largest holding was Amgen Inc, at 15.25% of the fund.

VanEck Biotech ETF largest holdings by share of net assets
#Holding% of fundValue
1Amgen Inc15.25%$60.32M
2Gilead Sciences Inc12.79%$50.58M
3Vertex Pharmaceuticals Inc9.10%$36.01M
4Regeneron Pharmaceuticals Inc6.21%$24.56M
5Revolution Medicines Inc5.27%$20.86M
6Argenx SE4.97%$19.67M
7Natera Inc4.92%$19.46M
8IQVIA Holdings Inc4.31%$17.03M
9Alnylam Pharmaceuticals Inc3.83%$15.16M
10Biogen Inc3.63%$14.35M
11Moderna Inc3.36%$13.30M
12Illumina Inc3.17%$12.54M
13United Therapeutics Corp2.83%$11.18M
14BeOne Medicines Ltd2.81%$11.11M
15Insmed Inc2.67%$10.56M
16Incyte Corp2.49%$9.86M
17Neurocrine Biosciences Inc2.08%$8.24M
18BioNTech SE1.94%$7.68M
19ICON PLC1.90%$7.52M
20Bio-Techne Corp1.54%$6.10M
21Charles River Laboratories International Inc1.50%$5.94M
22BioMarin Pharmaceutical Inc1.34%$5.29M
23QIAGEN NV1.06%$4.21M
24Tempus AI Inc0.98%$3.89M
25State Street Global Advisors0.06%$233.72K

Top 25 of 25 holdings, as of Jun 30, 2026. Percentages are of the fund's net assets.

What the fund owns

VanEck Biotech ETF holdings by asset type
Asset type% of fund
Stocks99.96%
Cash and short-term investments0.06%
VanEck Biotech ETF holdings by country, largest 5
Country% of fund
United States87.33%
Netherlands6.04%
Switzerland2.81%
Germany1.94%
Ireland1.90%

Shares of net assets from the fund's N-PORT report. Funds that borrow can add up to more than 100%, with borrowing (such as repurchase agreements) shown as a negative share.

Monthly total returns

Over the 3 months to Jun 30, 2026, VanEck Biotech ETF's total return was +8.09%, as reported to the SEC.

VanEck Biotech ETF monthly total returns
MonthTotal return
Jun 30, 2026+7.82%
May 31, 2026+1.64%
Apr 30, 2026−1.37%

The fund's own total returns as reported to the SEC (N-PORT), including reinvested distributions. Not the sample prices above.

Fund profile

Name
VanEck Biotech ETF
Ticker
BBH
Exchange
NASDAQ
Fund type
ETF
Trust
VanEck ETF Trust
SEC series ID
S000034406
SEC CIK
0001137360
Fractional shares
Yes

Recent SEC filings

Shareholder reports and prospectuses are filed by VanEck ETF Trust, the trust behind VanEck Biotech ETF, and cover all of its funds.

Frequently asked questions

What is BBH's price?

VanEck Biotech ETF (BBH) closed at $374.71 on Oct 9, 2026, down 0.54% from the previous close of $376.76.

What is BBH's expense ratio?

VanEck Biotech ETF's expense ratio is 0.35%: $35.00 a year on $10,000 invested.

What does BBH hold?

VanEck Biotech ETF held 25 investments worth $395.55M as of Jun 30, 2026. Its largest holding was Amgen Inc, at 15.25% of the fund. Its five largest holdings were Amgen Inc, Gilead Sciences Inc, Vertex Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc.

How has BBH performed?

Over the 3 months to Jun 30, 2026, VanEck Biotech ETF's total return was +8.09%, as reported to the SEC.

Sources and methodology

Holdings, net assets and monthly returns come from the fund's N-PORT filing with the SEC, as of Jun 30, 2026 (filed Aug 26, 2026). The expense ratio is from the fund's prospectus or shareholder report, as of Jan 31, 2026. Prices are generated sample data for development. Data sources and disclosures